Search Orphan Drug Designations and Approvals
-
Generic Name: | antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead |
---|---|
Date Designated: | 02/23/2021 |
Orphan Designation: | Treatment of multiple myeloma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-